BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36766747)

  • 1. Phosphorylation of IGFBP-3 by Casein Kinase 2 Blocks Its Interaction with Hyaluronan, Enabling HA-CD44 Signaling Leading to Increased NSCLC Cell Survival and Cisplatin Resistance.
    Coleman KL; Chiaramonti M; Haddad B; Ranzenberger R; Henning H; Al Khashali H; Ray R; Darweesh B; Guthrie J; Heyl D; Evans HG
    Cells; 2023 Jan; 12(3):. PubMed ID: 36766747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IGFBP-3 Blocks Hyaluronan-CD44 Signaling, Leading to Increased Acetylcholinesterase Levels in A549 Cell Media and Apoptosis in a p53-Dependent Manner.
    Price D; Muterspaugh R; Clegg B; Williams A; Stephens A; Guthrie J; Heyl D; Evans HG
    Sci Rep; 2020 Mar; 10(1):5083. PubMed ID: 32193421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of Insulin-Like Growth Factor-Binding Protein 3 With Hyaluronan and Its Regulation by Humanin and CD44.
    Muterspaugh R; Price D; Esckilsen D; McEachern S; Guthrie J; Heyl D; Evans HG
    Biochemistry; 2018 Oct; 57(39):5726-5737. PubMed ID: 30184438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer.
    Cortés-Sempere M; de Miguel MP; Pernía O; Rodriguez C; de Castro Carpeño J; Nistal M; Conde E; López-Ríos F; Belda-Iniesta C; Perona R; Ibanez de Caceres I
    Oncogene; 2013 Mar; 32(10):1274-83. PubMed ID: 22543588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer.
    Lee HY; Chun KH; Liu B; Wiehle SA; Cristiano RJ; Hong WK; Cohen P; Kurie JM
    Cancer Res; 2002 Jun; 62(12):3530-7. PubMed ID: 12068000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opposing Roles of IGFBP-3 and Heparanase in Regulating A549 Lung Cancer Cell Survival.
    Al Khashali H; Wareham J; Ray R; Haddad B; Coleman KL; Ranzenberger R; McCombs P; Guthrie J; Heyl D; Evans HG
    Cells; 2022 Nov; 11(22):. PubMed ID: 36428962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical determinants of the IGFBP-3-hyaluronan interaction.
    Dorandish S; Devos J; Clegg B; Price D; Muterspaugh R; Guthrie J; Heyl DL; Evans HG
    FEBS Open Bio; 2020 Aug; 10(8):1668-1684. PubMed ID: 32592613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyaluronan-CD44/RHAMM interaction-dependent cell proliferation and survival in lung cancer cells.
    Song JM; Im J; Nho RS; Han YH; Upadhyaya P; Kassie F
    Mol Carcinog; 2019 Mar; 58(3):321-333. PubMed ID: 30365189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
    Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
    J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronan-CD44 interaction promotes HPV 16 E6 oncogene-mediated oropharyngeal cell carcinoma survival and chemoresistance.
    Bourguignon LYW; Earle C; Shiina M
    Matrix Biol; 2019 May; 78-79():180-200. PubMed ID: 30077625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of hyaluronan-CD44-mediated growth, migration, and cisplatin resistance in head and neck cancer due to inhibition of Rho kinase and PI-3 kinase signaling.
    Torre C; Wang SJ; Xia W; Bourguignon LY
    Arch Otolaryngol Head Neck Surg; 2010 May; 136(5):493-501. PubMed ID: 20479382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of Cisplatin Resistance in Lung Cancer Cells by Nicotine, BDNF, and a β-Adrenergic Receptor Blocker.
    Ray R; Al Khashali H; Haddad B; Wareham J; Coleman KL; Alomari D; Ranzenberger R; Guthrie J; Heyl D; Evans HG
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44.
    Quan YH; Kim B; Park JH; Choi Y; Choi YH; Kim HK
    Exp Lung Res; 2014 Dec; 40(10):475-84. PubMed ID: 25299431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD44 inhibition attenuates EGFR signaling and enhances cisplatin sensitivity in human EGFR wild‑type non‑small‑cell lung cancer cells.
    Yin J; Zhang H; Wu X; Zhang Y; Li J; Shen J; Zhao Y; Xiao Z; Lu L; Huang C; Zhang Z; Du F; Wu Y; Kaboli PJ; Cho CH; Yuan D; Li M
    Int J Mol Med; 2020 Jun; 45(6):1783-1792. PubMed ID: 32236608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
    Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of AKT/NF‑κB signaling by eurycomalactone decreases human NSCLC cell viability and improves the chemosensitivity to cisplatin.
    Dukaew N; Chairatvit K; Pitchakarn P; Imsumran A; Karinchai J; Tuntiwechapikul W; Wongnoppavich A
    Oncol Rep; 2020 Oct; 44(4):1441-1454. PubMed ID: 32945500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional and posttranslational regulation of insulin-like growth factor binding protein-3 by Akt3.
    Jin Q; Lee HJ; Min HY; Smith JK; Hwang SJ; Whang YM; Kim WY; Kim YH; Lee HY
    Carcinogenesis; 2014 Oct; 35(10):2232-43. PubMed ID: 24942865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression.
    Bourguignon LY; Singleton PA; Zhu H; Diedrich F
    J Biol Chem; 2003 Aug; 278(32):29420-34. PubMed ID: 12748184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
    Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.